Sign In
Buy OTLK
$0.81
-0.0038 (-0.467%)
At Close: Jun 03, 2026
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
04:15pm, Thursday, 05'th Mar 2026
ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r
Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partner Mediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA
Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates
10:16am, Tuesday, 17'th Feb 2026
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.89 per share a year ago.
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
08:05am, Tuesday, 17'th Feb 2026
ISELIN, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
08:45am, Wednesday, 11'th Feb 2026
ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
10:56am, Wednesday, 07'th Jan 2026
Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
08:35am, Tuesday, 06'th Jan 2026
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again
08:18am, Friday, 02'nd Jan 2026
Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue.
U.S. stock futures rose on the first trading day of the year on Friday after missing the Santa Claus rally over the truncated week. Futures of major benchmark indices were higher. The Santa Claus trad
Apple, Taiwan Semiconductor Manufacturing And 3 Stocks To Watch Heading Into Friday
02:19am, Friday, 02'nd Jan 2026
U.S. stock futures up, Apple reduces Vision Pro production, TSMC gets U.S. export license, VS Media announces share combination.
Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of “Hold” from Analysts
01:23am, Friday, 02'nd Jan 2026
Oncobiologics, Inc. (NASDAQ: OTLK - Get Free Report) has been assigned an average rating of "Hold" from the six analysts that are covering the firm, Marketbeat reports. One equities research analyst h
US FDA declines to approve Outlook Therapeutics' eye disease drug
04:23pm, Wednesday, 31'st Dec 2025
The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' drug for a type of eye disease, the company said on Wednesday, marking another setback to its prolonged effort to br
FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLA FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLA
Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again
08:08pm, Sunday, 28'th Dec 2025
Outlook Therapeutics (OTLK) faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections and a 2025 recovery in share price. My bullish stance is underpinned by the NORSE
Outlook Therapeutics Announces New Employment Inducement Grants
05:00pm, Friday, 26'th Dec 2025
ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
